AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Clinuvel Pharmaceuticals Ltd (ASX:CUV)
11.32 AUD
+0.050 0.444%Sponsored Reports
Loading...
| Previous Close (in AUD) | 11.27 |
|---|---|
| Change | +0.050 0.444% |
| 52 W H/L (in AUD) | 17.652/9.755 |
| EBITDA (in AUD) | 51.728M |
| PE Ratio | 14.78 |
| Volume | 23237 |
| Diluted Eps TTM | 0.77 |
| Total Assets (in AUD) | 231.124M |
|---|---|
| Total Liabilities (in AUD) | 28.112M |
| Revenue TTM (in AUD) | 91.025M |
| Cash (in AUD) | 183.868M |
| Market Cap (in AUD) | 570.407 M |
| Revenue Per Share TTM | 1.817 |
| Gross Profit TTM (in AUD) | 82.675M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Clinuvel Pharmaceuticals Ltd
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900 and Parvysmelanotide (VLRX001), both alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone to produce cortisol and enables the combat of stress and regulation of immune responses, maintenance of blood pressure, moderation of blood sugar, and regulation of metabolism. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Philippe Jacques Wolgen M.B.A., M.D., MBA | CEO, MD & Director | 1963 |
| 2. | Mr. Darren M. Keamy | CFO & Company Sec. | 1973 |
| 3. | Dr. Dennis J. Wright | Chief Scientific Officer | NA |
| 4. | Mr. Lachlan Hay | Director of Global Operations | NA |
| 5. | Mr. Malcolm Bull | Head of Investor Relations | NA |
| 6. | Dr. Philippe Jacques Wolgen M.B.A., M.D. | CEO, MD & Director | 1963 |
| 7. | Mr. Darren Michael Keamy B.Com., CPA | CFO & Company Secretary | 1973 |
| 8. | Mr. Malcolm Bull | Head of Australian Operations & Investor Relations | NA |
| 9. | Dr. Rose Quadbeck-Diel | Senior Vice President of Regulatory Affairs | NA |
| 10. | Dr. Azza Hamila | Head of Quality & Drug Safety | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (AUD) | Price (AUD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
CSL
CSL Ltd |
-0.610 0.254% | 239.2 | 29.920 | 35.336 | 8.039 | 4.318 | 6.166 | 19.136 |
|
TLX
Telix Pharmaceuticals Ltd |
+0.180 0.676% | 26.88 | 209.430 | 67.114 | 12.462 | 17.178 | 12.298 | 104.073 |
|
MSB
Mesoblast Ltd |
-0.040 2.292% | 1.75 | 0.000 | 454.546 | 390.849 | 3.185 | 67.899 | -9.862 |
|
NEU
Neuren Pharmaceuticals Ltd |
+0.490 3.828% | 13.19 | 11.330 | 72.464 | 7.290 | 4.326 | 6.341 | 7.701 |
Income Statement
(Currency in AUD)| Breakdown | 30-06-2023 | 30-06-2022 | 30-06-2021 | 30-06-2020 | 30-06-2019 |
|---|---|---|---|---|---|
| Income Before Tax | 45.579M | 34.321M | 25.713M | 13.136M | 18.115M |
| Minority Interest | - | - | - | - | - |
| Net Income | 30.605M | 20.878M | 24.728M | 16.647M | 16.647M |
| Selling General Administrative | 22.567M | 17.712M | 12.76M | 1.148M | 8.93M |
| Gross Profit | 69.532M | 55.238M | 43.255M | 22.936M | 24.176M |
| Reconciled Depreciation | 0.789M | 0.758M | 0.861M | 0.428M | 0.214M |
| Ebit | 48.771M | 36.595M | 27.331M | 13.162M | 18.136M |
| Ebitda | 49.561M | 37.353M | 28.193M | 13.59M | 18.35M |
| Depreciation And Amortization | 0.789M | 0.758M | 0.861M | 0.428M | 0.214M |
| Operating Income | 44.126M | 35.547M | 28.567M | 12.251M | 18.136M |
| Other Operating Expenses | -18.414M | -11.069M | -12.641M | -4.932M | 14.571M |
| Interest Expense | 3.193M | 2.274M | 1.618M | 0.026M | 0.021M |
| Tax Provision | 14.974M | 13.442M | 0.984M | -3.51M | -0.019M |
| Interest Income | 2.453M | 0.444M | 0.342M | 0.628M | 0.859M |
| Net Interest Income | 0.713M | -1.83M | -1.276M | -0.026M | 0.544M |
| Income Tax Expense | 14.974M | 13.442M | 0.984M | -3.51M | -0.019M |
| Total Revenue | 78.321M | 65.722M | 47.976M | 32.565M | 31.048M |
| Total Operating Expenses | 25.429M | 19.908M | 15.031M | 11.545M | 7.7M |
| Cost Of Revenue | 8.79M | 10.484M | 4.72M | 9.63M | 6.871M |
| Total Other Income Expense Net | 0.763M | 0.821M | -1.236M | 0.781M | -0.021M |
| Net Income From Continuing Ops | 30.605M | 20.878M | 24.728M | 16.647M | 18.134M |
| Net Income Applicable To Common Shares | 30.605M | 20.878M | 24.728M | 16.647M | 18.134M |
Balance Sheet
(Currency in AUD)| Breakdown | 30-06-2024 | 30-06-2023 | 30-06-2022 | 30-06-2021 | 30-06-2020 |
|---|---|---|---|---|---|
| Total Assets | 231.124M | 193.714M | 143.95M | 108.568M | 81.542M |
| Intangible Assets | 0.185M | - | - | - | - |
| Other Current Assets | 1.33M | 1.07M | 1.039M | 0.882M | 0.509M |
| Total Liab | 28.112M | 29.082M | 18.39M | 9.83M | 7.873M |
| Total Stockholder Equity | 203.011M | 164.631M | 125.559M | 98.737M | 73.669M |
| Other Current Liab | 22.497M | 22.703M | 13.473M | 4.051M | 6.832M |
| Common Stock | 168.802M | 151.849M | 151.849M | 151.849M | 151.849M |
| Capital Stock | 168.802M | 151.849M | 151.849M | 151.849M | 151.849M |
| Retained Earnings | 29.964M | -9.774M | -38.402M | -58.13M | -80.037M |
| Good Will | - | 0.185M | 0.185M | 0.185M | 0.185M |
| Other Assets | - | 1.06M | 0.482M | 2.931M | 3.812M |
| Cash | 183.868M | 156.814M | 121.509M | 82.691M | 66.747M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 25.212M | 25.495M | 13.732M | 8.707M | 6.66M |
| Current Deferred Revenue | - | -0.301M | -0.315M | 2.074M | -1.814M |
| Net Debt | -182.989M | -155.814M | -120.253M | -81.388M | -65.427M |
| Short Term Debt | 0.37M | 0.301M | 0.315M | 0.258M | 0.212M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 0.88M | 1M | 1.257M | 1.303M | 1.32M |
| Other Stockholder Equity | - | -142.075M | -113.447M | -93.72M | -70.216M |
| Property Plant Equipment | - | 2.851M | 2.7M | 2.603M | 2.389M |
| Total Current Assets | 222.064M | 189.618M | 140.583M | 102.848M | 75.156M |
| Long Term Investments | 0.134M | - | - | - | - |
| Short Term Investments | 148.668M | 133.93M | 98.659M | 48.117M | 42.873M |
| Net Receivables | 26.238M | 22.215M | 16.202M | 16.089M | 6.613M |
| Long Term Debt | - | - | - | - | - |
| Inventory | 10.627M | 9.519M | 1.832M | 3.187M | 1.288M |
| Accounts Payable | 2.345M | 2.792M | 0.259M | 2.324M | 1.43M |
| Accumulated Other Comprehensive Income | 4.245M | 22.556M | 12.112M | 5.018M | 1.856M |
| Non Currrent Assets Other | - | -3.036M | -2.885M | -2.788M | -2.574M |
| Non Current Assets Total | 9.06M | 4.096M | 3.367M | 5.719M | 6.386M |
| Capital Lease Obligations | 0.88M | 1M | 1.257M | 1.303M | 1.32M |
| Long Term Debt Total | - | 0.699M | 0.941M | 1.045M | 1.107M |
Cash Flow
(Currency in AUD)| Breakdown | 30-06-2023 | 30-06-2022 | 30-06-2021 | 30-06-2020 | 30-06-2019 |
|---|---|---|---|---|---|
| Investments | -1.028M | -0.434M | -0.854M | -0.889M | -0.258M |
| Total Cashflows From Investing Activities | -1.028M | -0.434M | -0.854M | -0.889M | -0.258M |
| Total Cash From Financing Activities | -2.24M | -1.504M | -1.48M | -1.486M | -1.031M |
| Net Income | 30.605M | 20.878M | 24.728M | 15.051M | 18.134M |
| Change In Cash | 35.304M | 38.818M | 15.944M | 12.478M | 18.07M |
| Begin Period Cash Flow | 121.509M | 82.691M | 66.747M | 54.269M | 36.198M |
| End Period Cash Flow | 156.814M | 121.509M | 82.691M | 66.747M | 54.269M |
| Total Cash From Operating Activities | 36.912M | 39.872M | 19.262M | 14.188M | 18.456M |
| Depreciation | 0.741M | 0.717M | 0.82M | 0.428M | 0.214M |
| Other Cashflows From Investing Activities | - | - | - | - | - |
| Dividends Paid | -1.976M | -1.235M | -1.235M | -1.224M | 0.957M |
| Change To Inventory | -7.688M | 1.355M | -1.899M | 0.848M | -1.495M |
| Sale Purchase Of Stock | - | - | - | - | - |
| Other Cashflows From Financing Activities | -0.264M | -0.268M | -0.245M | -0.243M | -0.258M |
| Capital Expenditures | 1.028M | 0.434M | 0.854M | 0.889M | 0.258M |
| Change In Working Capital | -13.7M | 1.241M | -11.375M | -1.608M | 0.441M |
| Other Non Cash Items | 5.567M | 18.277M | -6.286M | -1.29M | -18.348M |
| Free Cash Flow | 35.885M | 39.438M | 18.408M | 13.3M | 18.198M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Bernstein Fund, Inc.-International Small Cap Portfolio | 4 years ago | 87490 |
| 2. | Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund | 4 years ago | 246587 |
| 3. | iShares MSCI EAFE Small Cap ETF | 4 years ago | 177672 |
| 4. | iShares Core MSCI EAFE ETF | 4 years ago | 182269 |
| 5. | Schwab Strategic Tr-Schwab International Small Cap Equity ETF | 4 years ago | 53643 |
| 6. | DFA International Core Equity Portfolio | 4 years ago | 42853 |
| 7. | Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index | 4 years ago | 95629 |
| 8. | Vanguard International Stock Index-Total Intl Stock Indx | 4 years ago | 647827 |
| 9. | DFA Asia Pacific Small Company Series | 4 years ago | 108279 |
| 10. | College Retirement Equities Fund-Stock Account | 4 years ago | 112159 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...
